News

Corona Remedies announced that the Board of Directors of the Company at its meeting held on 11 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Corona Remedies rose 43.68% to Rs 45.33 crore in the quarter ended March 2026 as against Rs 31.55 crore during the previous quarter ended March 2025. Sales rose 20.23% to Rs 353.09 crore in the quarter ended March 2026 as against Rs 293.69 crore during the previous quarter ended March 2025.For the full year,net profit rose 23.88% to Rs 185.12 crore in the year ended March 2026 as against Rs 149.43 crore during the previous year ended March 2025. Sales rose 17.28% to Rs 1403.18 crore in the year ended March 2026 as against Rs 1196.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales353.09293.69 20 1403.181196.42 17 OPM %17.5618.46 -20.9120.06 - PBDT65.0353.65 21 297.39235.69 26 PBT54.7443.61 26 259.52198.53 31 NP45.3331.55 44 185.12149.43 24 Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 11 May 2026.

Net profit of Corona Remedies declined 8.19% to Rs 41.27 crore in the quarter ended December 2025 as against Rs 44.95 crore during the previous quarter ended December 2024. Sales rose 15.03% to Rs 342.42 crore in the quarter ended December 2025 as against Rs 297.69 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales342.42297.69 15 OPM %24.2923.32 - PBDT83.7667.97 23 PBT74.3158.28 28 NP41.2744.95 -8 Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 2 February 2026.Powered by Capital Market - Live News